The effect of concomitant carcinoma in situ on neoadjuvant chemotherapy for urothelial cell carcinoma of the bladder: inferior pathological outcomes but no effect on survival.

Abstract

PURPOSE:

It is generally believed that carcinoma in situ is refractory to chemotherapy but specific data are lacking to validate this. We evaluated the effect of concomitant clinical carcinoma in situ on cancer specific outcomes after neoadjuvant chemotherapy for muscle invasive bladder cancer.

MATERIALS AND METHODS:

We performed an institutional review board approved, multi-institutional, retrospective review of the records of patients treated with neoadjuvant chemotherapy followed by radical cystectomy for muscle invasive bladder cancer from 2008 to 2012. Pretreatment clinical variables were collected and patients were stratified by the presence of clinical carcinoma in situ on precystectomy transurethral bladder tumor resection specimens. Pathological outcomes, including the complete response rate (pT0N0Mx) after neoadjuvant chemotherapy, were compared between the 2 groups. Recurrence-free, cancer specific and overall survival was analyzed.

RESULTS:

Of 189 patients who met study criteria 56 (29.6%) had concomitant carcinoma in situ. The condition was associated with a significant decrease in the pathological complete response rate (10.7% vs 26.3%, p = 0.02). This difference was significant on univariate and multivariable analysis (OR 0.34, 95% CI 0.13-0.85, p = 0.02 and OR 0.31, 95% CI 0.12-0.81, p = 0.02, respectively). Despite the decreased complete response rate clinical carcinoma in situ was not associated with a difference in recurrence-free, cancer specific or overall survival. Additionally, when down-staging to pathological carcinoma in situ only disease was considered a complete response, there was no significant change in recurrence-free, cancer specific or overall survival.

CONCLUSIONS:

Concomitant carcinoma in situ is associated with a decrease in the complete response rate but this does not appear to impact the survival outcome.

• Authors: William P Parker, Phillip L Ho, Jonathan J Melquist, Katie Scott, Jeffrey M Holzbeierlein, Ernesto Lopez-Corona, Ashish M Kamat, Eugene K Lee
• Journal: The Journal of urology (J Urol) Vol. 193 Issue 5 Pg. 1494-9 (May 2015) ISSN: 1527-3792 [Electronic] United States
• PMID: 25451834 (Publication Type: Evaluation Study, Journal Article, Multicenter Study, Validation Study)
• Copyright: Copyright © 2015 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Topics

• Carcinoma in Situ (drug therapy, pathology, surgery)
• Carcinoma, Transitional Cell (drug therapy, pathology, surgery)
• Chemotherapy, Adjuvant
• Cystectomy
• Humans
• Neoadjuvant Therapy
• Neoplasms, Multiple Primary (drug therapy, pathology, surgery)
• Remission Induction
• Retrospective Studies
• Treatment Outcome
• Urinary Bladder Neoplasms (drug therapy, pathology, surgery)